Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Leukemia 2Uterine Cervical Neoplasms 1Rectal Neoplasms 1Prostatic Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Myelodysplastic Syndromes 1Lymphoma 1Lichen Planus, Oral 1Head and Neck Neoplasms 1Gastrointestinal Neoplasms 1Erectile Dysfunction 1Anemia 1

Interventions

Oxaliplatin 180Capecitabine 174Fluorouracil 154Radiotherapy 107Leucovorin 107Irinotecan 93Bevacizumab 69Surgical Procedures, Operative 49Cetuximab 39Drug Therapy 38Radiation 35Neoadjuvant Therapy 33Folfox protocol 29Chemoradiotherapy 29XELOX 22Magnetic Resonance Spectroscopy 21Chemotherapy, Adjuvant 21Radiotherapy, Intensity-Modulated 19Surveys and Questionnaires 17Proctectomy 16Biopsy 16Early Intervention, Educational 14trifluridine tipiracil drug combination 12Panitumumab 12Floxuridine 12tislelizumab 11regorafenib 11Nivolumab 11Laparoscopy 11Celecoxib 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Rectal Neoplasms × Erythropoietin × Clear all
NCT00254436 2018-10-25

A Double-Blind, Randomized, Placebo-Controlled Study of the Efficacy and Safety of Weekly Procrit Given to Gastric or Rectal Patients

M.D. Anderson Cancer Center

Phase 3 Terminated
50 enrolled
Gastrointestinal

Gastrointestinal Neoplasms, Rectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡